<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468689</url>
  </required_header>
  <id_info>
    <org_study_id>CR9107262</org_study_id>
    <nct_id>NCT00468689</nct_id>
  </id_info>
  <brief_title>Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.</brief_title>
  <official_title>A Two-Part Dose-Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SB-751689 When Administered as an Oral Formulation at Supratherapeutic Dose Levels in Healthy Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and exposure of SB-751689 when administered&#xD;
      alone at supratherapeutic doses and when SB-751689 is co administered with ketoconazole, a&#xD;
      PGP/CYP3A4 inhibitor that increases exposure of SB-751689. Data from this study will enable&#xD;
      the planning and conduct of a QTc study for SB-751689.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of SB-751689 doses determined from clinical safety and tolerability data from all adverse event reporting, 12-lead ECGs, vital signs, nursing/physician observation, and safety laboratory tests</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK and of SB-751689 as determined by AUC, Cmax, tmax, and half-life. PD effects (PTH, serum Ca) as determined by AUC, Emax, tmax, maximum change and % change from baseline, duration of effect, duration above ULN for PTH.</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-751689 oral tablets (100 and 400 ng)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole (NIZORAL) oral tablets (200 mg)</intervention_name>
    <other_name>SB-751689 oral tablets (100 and 400 ng)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged 18-60yrs, with BMI of 19-31kg/m2.&#xD;
&#xD;
          -  Females must be of non-childbearing potential.&#xD;
&#xD;
          -  Subjects must be able to give consent and comply with restrictions of study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant abnormality from history, physical, 12-lead ECG, Holter&#xD;
             monitoring, or clinical laboratory examination.&#xD;
&#xD;
          -  Positive urine drug screen.&#xD;
&#xD;
          -  Positive urine test for alcohol.&#xD;
&#xD;
          -  Contine levels indicative of smoking.&#xD;
&#xD;
          -  Positive HIV or Hep B and/or C assay.&#xD;
&#xD;
          -  History or smoking in last year or &gt;10 pack/year history of smoking overall.&#xD;
&#xD;
          -  History of regular alcohol consumption (7 units/week for women and 14 units/week for&#xD;
             men) within 6 months of study.&#xD;
&#xD;
          -  History of drug abuse within 6 months of study.&#xD;
&#xD;
          -  Participation in another drug trial within 30 days of first dose.&#xD;
&#xD;
          -  Exposure to more than 4 new chemical entities within 12 months of first dose.&#xD;
&#xD;
          -  Use of prescription and non-prescription drugs including dietary supplements, herbals&#xD;
             and St. John's wort within 14 days of first dose.&#xD;
&#xD;
          -  Consumption of red wine, grapefruit, grapefruit juice and grapefruit products within&#xD;
             14 days of first dose.&#xD;
&#xD;
          -  Donation of blood in excess of 500 mL within 56 days of dosing.&#xD;
&#xD;
          -  Evidence of renal, hepatic or biliary impairment.&#xD;
&#xD;
          -  History of serious gastrointestinal disease or history of gastrointestinal surgical&#xD;
             procedure that might affect absorption of study drug.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications.&#xD;
&#xD;
          -  History of clinically significant cardiovascular disease.&#xD;
&#xD;
          -  History of pernicious anemia, pancreatitis, osteosarcoma or kidney stones. Medical&#xD;
             conditions which might alter bone metabolism.&#xD;
&#xD;
          -  Liver function tests above ULN at screening and PTH, glucose, and CPK outside the&#xD;
             reference range at screening.&#xD;
&#xD;
          -  Males unwilling to refrain from fathering a child during the study and for 14 days&#xD;
             following the last dose of study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>May 1, 2007</study_first_submitted>
  <study_first_submitted_qc>May 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2007</study_first_posted>
  <last_update_submitted>October 9, 2008</last_update_submitted>
  <last_update_submitted_qc>October 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>SB-751689,</keyword>
  <keyword>Calcium-sensing receptor antagonist (CaR),</keyword>
  <keyword>Osteoporosis,</keyword>
  <keyword>Parathyroid hormone (PTH),</keyword>
  <keyword>Oral dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

